Hera Women's Health Highlights Sera Prognostics PRIME Trial Results Led by Brian K. Iriye, MD Showing Biomarker-Guided Care Improves Newborn Outcomes and Reduces NICU Use
Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications [Yahoo! Finance]
Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications
With 40% ownership, Sera Prognostics, Inc. (NASDAQ:SERA) has piqued the interest of institutional investors [Yahoo! Finance]
Sera Prognostics (NASDAQ:SERA) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.